Liver transplantation for nonresectable liver metastases from colorectal cancer

Annals of Surgery

Volumn 257, Issue 5, 2013, Pages 800-806

  Hagness, Morten ^a,b   Foss, Aksel ^a,b   Line, Pål Dag ^a   Scholz, Tim ^a   Jørgensen, Pål Foyn ^a   Fosby, Bjarte ^a,b   Boberg, Kirsten Muri ^c   Mathisen, Øystein ^d   Gladhaug, Ivar P ^b,d   Egge, Tor Skatvedt ^a   Solberg, Steinar ^a   Hausken, John ^a   Dueland, Svein ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c Department of Transplantation Medicine   (Norway)

^d Section for Hepato Pancreato Biliary Surgery   (Norway)

Author keywords

colorectal liver metastases; liver transplantation; malignancy; non resectable; prospective study

Indexed keywords

BASILIXIMAB; BEVACIZUMAB; CETUXIMAB; CORTICOSTEROID; IRINOTECAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OXALIPLATIN; RAPAMYCIN;

ABDOMINAL BLEEDING; ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; BASAL CELL CARCINOMA; BILE LEAKAGE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHOLESTASIS; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEMATOMA; HEPATIC ARTERY THROMBOSIS; HEPATORENAL SYNDROME; HERNIA; HUMAN; INCISIONAL HERNIA; INTESTINE OBSTRUCTION; ISCHEMIC OPTIC NEUROPATHY; KAPLAN MEIER METHOD; LIVER GRAFT REJECTION; LIVER METASTASIS; LIVER TRANSPLANTATION; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PILOT STUDY; PNEUMONIA; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE INFECTION; PRIMARY GRAFT DYSFUNCTION; PRIMARY TUMOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT CONTRAINDICATION; VASCULAR DISEASE; VIRUS HEPATITIS; WOUND COMPLICATION; WOUND DEHISCENCE; WOUND INFECTION;

AGED; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; PILOT PROJECTS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84876295660     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3182823957     Document Type: Article

References (38)

1. Masuoka HC, Rosen CB. Transplantation for cholangiocarcinoma. Clin Liver Dis. 2011;15:699-715.
2. Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10:35-43.
3. Mathe Z, Tagkalos E, Paul A, et al. Liver transplantation for hepatic metastases of neuroendocrine pancreatic tumors: a survival-based analysis. Transplantation. 2011;91:575-582.
4. Hoti E, Adam R. Liver transplantation for primary and metastatic liver cancers. Transpl Int. 2008;21:1107-1117.
5. Fernandez FG, Drebin JA, Linehan DC, et al. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg. 2004;240:438-447.
6. Quan D, Gallinger S, Nhan C, et al. The role of liver resection for colorectal cancer metastases in an era of multimodality treatment: a systematic review. Surgery. 2012;151:860-870.
7. Primrose JN. Surgery for colorectal liver metastases. Br J Cancer. 2010;102:1313-1318.
8. Van CE, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408-1417.
9. Sanoff HK, Sargent DJ, Campbell ME, et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol. 2008;26:5721-5727.
10. Foss A, Adam R, Dueland S. Liver transplantation for colorectal liver metastases: revisiting the concept. Transpl Int. 2010;23:679-685.
11. Muhlbacher F, Huk I, Steininger R, et al. Is orthotopic liver transplantation a feasible treatment for secondary cancer of the liver? Transplant Proc. 1991;23:1567-1568.
12. Kappel S, Kandioler D, Steininger R, et al. Genetic detection of lymph node micrometastases: a selection criterion for liver transplantation in patients with liver metastases after colorectal cancer. Transplantation. 2006;81:64-70.
13. United Network for Organ Sharing Web page. 2011. Available at: http://www.unos.org. Accessed December 1, 2011.
14. European Liver Transplant Registry. Data Analysis Booklet. Paris: European Liver Transplant Registry; 2007: Available at: http://www.eltr.org. Accessed December 1, 2011.
15. Scandiatransplant. The Nordic Liver Transplant Registry annual report 2009. Available at: www.scandiatransplant.org/ANNUAL REPORT 2009 FINAL. pdf. Accessed December 1, 2011.
16. Liang W, Wang D, Ling X, et al. Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis. Liver Transpl. 2012;18:62-69.
17. Schnitzbauer AA, Zuelke C, Graeb C, et al. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free im-munosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer. 2010;10:190.
18. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma. Cancer. 2010;116:4256-4265.
19. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309-318.
20. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205-213.
21. Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:2311-2319.
22. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357:2040-2048.
23. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757-1765.
24. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and ce-tuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-345.
25. Pulitano C, Bodingbauer M, Aldrighetti L, et al. Liver resection for col-orectal metastases in presence of extrahepatic disease: results from an international multi-institutional analysis. Ann Surg Oncol. 2011;18:1380-1388.
26. Ayez N, Lalmahomed ZS, van der Pool AE, et al. Is the clinical risk score for patients with colorectal liver metastases still useable in the era of effective neoadjuvant chemotherapy? Ann Surg Oncol. 2011;18:2757-2763.
27. House MG, Ito H, Gonen M, et al. Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1, 600 patients during two decades at a single institution. J Am Coll Surg. 2010;210:744-745.
28. Settmacher U, Dittmar Y, Knosel T, et al. Predictors of long-term survival in patients with colorectal liver metastases: a single center study and review of the literature. Int J Colorectal Dis. 2011;26:967-981.
29. Kornprat P, Jarnagin WR, Gonen M, et al. Outcome after hepatectomy for multiple (four or more) colorectal metastases in the era of effective chemotherapy. Ann Surg Oncol. 2007;14:1151-1160.
30. Adam R, Hoti E, Bredt LC. Evolution of neoadjuvant therapy for extended hepatic metastases-have we reached our (non-resectable) limit? J Surg Oncol. 2010;102:922-931.
31. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693-699.
32. Pelletier SJ, Schaubel DE, Punch JD, et al. Hepatitis C is a risk factor for death after liver retransplantation. Liver Transpl. 2005;11:434-440.
33. Rowe IA, Barber KM, Birch R, et al. Retransplantation for graft failure in chronic hepatitis C infection: a good use of a scarce resource? Wo r l d J G a s-troenterol. 2010;16:5070-5076.
34. Magee JC, Barr ML, Basadonna GP, et al. Repeat organ transplantation in the United States, 1996-2005. Am J Transplant. 2007;7:1424-1433.
35. Vivarelli M, Cucchetti A, La BG, et al. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg. 2008;248:857-862.
36. Gantxegi A, Caralt M, Bilbao I, et al. Evolution of biliary complications after liver transplantation: a single European series. Transplant Proc. 2011;43:745-748.
37. Andersen MH, Dueland S, Hagness M, et al. Quality of life following liver transplantation in patients with liver metastases from colorectal carcinoma. Scand J Caring Sci. 2012;26:713-719.
38. D'Angelica M, Kornprat P, Gonen M, et al. Effect on outcome of recurrence patterns after hepatectomy for colorectal metastases. Ann Surg Oncol. 2011;18:1096-1103.